RESEARCH ARTICLE

F-18 FDG PET/CT in 26 patients with SAPHO syndrome: a new vision of clinical and bone scintigraphy correlation

Xiaochuan Sun¹†, Chen Li²†, Yihan Cao¹†, Ximin Shi³, Li Li⁴, Weihong Zhang⁵, Xia Wu¹, Nan Wu⁶, Hongli Jing³* and Wen Zhang¹*

Abstract

Backgrounds: Whole-body bone scintigraphy (WBBS) and MRI are widely used in assessment of patients with synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. However, the value of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) in SAPHO syndrome was unclear. The aim of this study was to characterize the manifestation of SAPHO syndrome on ¹⁸F-FDG PET/CT and explore its relationship with clinical symptoms and WBBS.

Methods: Twenty-six patients who suffered from SAPHO syndrome and had undergone whole-body ¹⁸F-FDG PET/CT were recruited in Peking Union Medical College Hospital from 2004 to 2016. Clinical manifestations and laboratory findings were recorded for all patients. Imaging data on ¹⁸F-FDG PET/CT and WBBS were collected and analyzed retrospectively.

Results: All the 26 patients (20 females and 6 males) exhibited skeletal abnormalities on ¹⁸F-FDG PET/CT. Multiple skeletal lesions affecting the anterior chest wall or spine with low to moderate ¹⁸F-FDG uptake and coexistence of osteolysis and osteosclerosis presented as the typical features of SAPHO syndrome. Sixteen (61.5%) patients had abnormal ¹⁸F-FDG uptake outside the osteoarticular system. PET scan had moderate to substantial agreement with CT and WBBS in revealing lesions in the anterior chest wall and axial skeleton. Nonetheless, the correlation between increased ¹⁸F-FDG uptake and clinical symptoms was weak.

Conclusions: SAPHO syndrome exhibits characteristic features on ¹⁸F-FDG PET/CT. It showed comparable capacity in revealing skeletal lesions with bone scintigraphy.

Keywords: SAPHO, [¹⁸F] FDG PET/CT, Bone scintigraphy, Osteoarticular symptoms

Background

SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome is a rare disease which was firstly proposed by Chamot et al. in 1987 as an umbrella term for a spectrum of osteoarticular and dermatological disorders [1]. High heterogeneity has been demonstrated in its clinical manifestations, in which bone disease is a core element [2]. Despite recent advances in our understanding of SAPHO syndrome, the precise pathogenesis largely remains elusive [3]. The diagnosis of SAPHO is based on clinical, radiological, and sometimes histological features, with no standard criteria accepted universally [3].

SAPHO syndrome is considered to be a rare disease, with a prevalence lower than 1/10,000 in Caucasians [4]. However, exact epidemiological data is still unavailable; the real prevalence is probably underestimated due to lack of awareness of this disease and the absence of skin lesions in some patients [5, 6]. Despite the good overall prognosis of most patients, SAPHO appears to be a...
chronic disease with recurrent exacerbations and remissions, severely undermining patients’ general health and quality of life [6, 7].

Radiological examinations play an important role in differential diagnosis and evaluation of osteoarticular abnormalities in SAPHO syndrome, especially subclinical foci [8]. Currently, whole-body bone scintigraphy and MRI are commonly used, which allows for early diagnosis and higher sensitivity compared with conventional radiographic imaging [3, 9]. The use of F-18 fluorodeoxyglucose-petem tomography/computed tomography (18F-FDG PET/CT) in SAPHO has been described by several case reports [10–21] (Table 1) and has been demonstrated to be effective in excluding metastatic disease in challenging cases and differentiating active lesions from inactive lesions [22]. However, few studies on the value of PET/CT in SAPHO syndrome have been performed in relatively large population.

The aim of this study was to characterize the manifestation of SAPHO syndrome on 18F-FDG PET/CT in 26 patients and explore its relationship with clinical symptoms and whole-body bone scintigraphy.

**Methods**

**Study population**

Twenty-six patients who fulfilled the diagnostic criteria for SAPHO syndrome proposed by Benhamou et al. [4] and had undergone whole-body 18F-FDG PET/CT after 6 months prior to the onset of symptoms were recruited in Peking Union Medical College Hospital (PUMCH) from 2004 to 2016. Inclusion criteria included osteoarticular manifestations with acne conglobate, acne fulminans or hidradenitis suppurativa, osteoarticular manifestations with palmoplantar pustulosis (PPP), hyperostosis (of the anterior chest wall (ACW), limbs, or spine) with or without dermatosis, and CRMO involving the axial or peripheral

**Table 1** Summary of reported patients with SAPHO syndrome undergoing PET/CT

| Author/year       | Age | Sex | Skin lesions | Sites of osteoarticular symptoms | PET/CT Time from onset | Sites of increased tracer uptake | SUVmax | Site of lesions on CT | Characteristics of lesions on CT | Bone scintigraphy | ESR (mm/h) | CRP (mg/dL) |
|------------------|-----|-----|--------------|---------------------------------|------------------------|---------------------------------|--------|----------------------|---------------------------------|---------------|------------|-------------|
| Kohlfluenter et al. 2003 [10] | 45  | M   | PPP          | Shoulder, tibia, ankle          | < 36                   | Tibia, ankle                 | NA     | ACW                  | Hyperostosis                    | ACW, tibia     | NA         | NA          |
| Pichler et al. 2003 [11]         | 48  | M   | PPP, acne, seborrheias | ACW                            | > 48                   | ACW                           | NA     | ACW                  | Sclerosis                       | ACW, NA       | NA         | NA          |
| Shibakuki et al. 2006 [12]       | 57  | M   | PPP, acne    | ACW                            | ~ 240                  | Normal                        | NA     | CS                   | Bone defect, consolidation       | ACW, CS, rib 6,7 | 15         | Normal      |
| Inoue et al. 2007 [13]           | 74  | F   | PPP          | Back                            | 300                    | CS, TS                        | NA     | CS, TS, LS           | Sclerosis, syndesmophyte, osteophyte formation | CS, TS, LS, SI | Elevated   | Elevated    |
| Takeuchi et al. 2007 [14]        | 50  | F   | None         | Neck, back, lumbar              | 168                    | ACW, CS, LS, SI, wrist        | 1.6    | CS, LS, femoral neck | Osteosclerosis, osteolysis        | ACW, CS, LS, SI, femoral neck | 87         | 2.5         |
| Patel et al. 2009 [15]           | 20  | F   | PPP          | Back                            | N/A                    | ACW, TS, SI                   | NA     | NA                   | NA                              | SC, TS, SI     | NA         | NA          |
| Abuhid et al. 2010 [16]          | 44  | F   | PPP          | ACW, SI                         | 36                     | ACW, SI                       | 2.18   | ACW, SI              | Sclerosis, irregularities         | ACW, SI       | NA         | NA          |
| Canbaz et al. 2010 [17]          | 18  | F   | None         | Diffuse, prominent in back      | 9                      | TS, LS, pelvis                | NA     | NA                   | NA                              | Spine, pelvic bones | 74         | NA          |
| Nakamura et al. 2010 [18]        | 60  | F   | None         | Ankle, back                     | N/A                    | CS, LS, SI                    | 6.1    | NA                   | NA                              | 99            | 6.379      |             |
| Namkoong et al. 2015 [19]        | 62  | M   | None         | ACW                             | 3                      | ACW                           | 4.0    | None                 | Normal                         | NA            | 13.45      |             |
| Ikeda et al. 2015 [20]           | 60  | F   | Acne         | ACW, hands                      | N/A                    | ACW                           | NA     | ACW                  | Hyperostosis                   | NA            | NA         | NA          |
| Dong et al. 2016 [21]            | 60  | F   | PPP          | Back                            | 2                      | TS, SS                        | NA     | TS, SS               | Osteolysis                      | TS, SI         | NA         | NA          |
| Dong et al. 2016 [21]            | 51  | F   | None         | Back                            | 7                      | ACW, LS, SI                   | NA     | ACW, SI              | Osteosclerosis                  | ACW, spine, SI | NA         | NA          |

ACW includes the costochondral, sternoclavicular, manubriosternal, and costosternal articulation, sternum, clavicles, and anterior ribs
ACW anterior chest wall, SI sacroiliac, CS cervical spine, TS thoracic spine, LS lumbar spine, NA not applicable

*With absent uptake in the left SC region
skeleton with or without dermatosis. Exclusion criteria included septic osteomyelitis, infectious chest wall arthritis, and infectious PPP, palmoplantar keratoderma, and diffuse idiopathic skeletal hyperostosis except for fortuitous association and osteoarticular manifestations of retinoid therapy. A written informed consent was obtained from each patient. The Ethics Committee of Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, approved this study (number of Ethics documents: ZS-944).

Clinical evaluation
All patients’ medical data were collected, including age, sex, skin lesions, sites of osteoarticular symptoms, and time interval between onset of SAPHO-related symptoms and PET/CT examination. Laboratory tests included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), anti-nuclear antibody (ANA), rheumatoid factor (RF), and HLA-B27. ESR and CRP were recorded in the same episode of disease when PET/CT was performed. One episode of disease was defined as a period of time shorter than 2 months, in which no changes of patients’ conditions were reported, including the site, quality, and intensity of pain, and no medications were administrated except for non-steroidal anti-inflammatory drugs (NSAIDs). Some patients had undergone tissue biopsy to aid the diagnosis. Their pathological characteristics were also collected.

Imaging assessment
Whole-body 18F-FDG PET/CT and 99mTc static whole-body bone scintigraphy (WBBS) available on recruitment were collected for all patients. When reporting bone lesions, the costochondral, sternoclavicular, manubriosternal, and costosternal joints, sternum, clavicles, and anterior ribs were grouped as anterior chest wall (ACW). For standard uptake value (SUV) of PET/CT in each patient, the highest one (SUVmax) among all the sites of bone lesions or extra-osteoarticular lesions was recorded separately.

Statistical analysis
Continuous data were expressed as means ± standard deviation, while categorical variables were described in numbers and percentages. Agreement between functional part of PET/CT and concurrent clinical symptoms, WBBS, and the structural part of PET/CT were assessed using cross-tabulation quantified by Cohen’s $\kappa$, positive agreement, and negative agreement [23]. Each anatomical region (the ACW, the cervical, thoracic, lumbar, and sacral spine, and the sacroiliac joint) was analyzed separately. Peripheral lesions were not included in agreement assessment due to their low frequency. All tests were two-tailed with the significant level of 0.05. Data were analyzed using SPSS 15.0.

Results

Demographic and clinical characteristics
Twenty women and six men were included in the study. The mean age at onset was 44.6 years, while the mean age of performing PET/CT scans was 47.9 years. Almost all patients had both osteoarticular and cutaneous symptoms. Only one (4%) patient showed no sign of skin lesions. The most common dermatological manifestation was palmoplantar pustulosis (PPP), affecting 23 (89%) patients. Severe acne (SV) and psoriasis vulgaris (PV) were seen in 4 (15%) and 2 (8%) patients, respectively. All patients suffered from pain in ACW. Other common sites of osteoarticular symptoms were the pelvis, shoulder, back, hip, and neck, showing an obvious predilection for axial bone and joints.

Laboratory findings were considerably variable among patients, with ESR ranging from 3 to 115 mm/h and CRP from 2 to 120 mg/dl. Over 60% patients had both an abnormal ESR (>20 mm/h) and an abnormal CRP (>5 mg/dl). No patients were found to be HLA-B27 positive. Nine patients underwent bone biopsies in order to exclude infectious or metastatic diseases. All biopsies were performed right after PET/CT examination, and the site of sampling was selected as the site with highest SUV. The most frequent finding was aseptic inflammation with infiltration of inflammatory cells, typically including lymphocytes and plasma cells. Lesions with subacute inflammation, chronic inflammation, and fibrosis and hyperostosis were revealed in different patients (Additional file 1: Table S1).

Whole-body bone scintigraphy
Twenty-five (96%) patients underwent 99mTc-MDP whole-body bone scintigraphy. All had increased tracer uptake in ACW. Twenty-two (88%) patients had spinal lesions detected by bone scintigraphy, including 15 (60%), 11 (44%), 4 (16%), and 3 (12%) patients for lumbar, thoracic, cervical, and sacral spine, respectively. Additionally, 8 (32%) patients had abnormal uptake in sacroiliac joint and 9 (36%) in non-axial bones.

18F-FDG PET/CT
All the 26 patients exhibited skeletal abnormalities on 18F-FDG PET, of which 22 (84.6%) showed multiple bone lesions on PET imaging. The ACW was the most frequently involved site with 23 (88.5%) patients affected (Fig. 1a). Increased 18F-FDG uptake in lumbar, thoracic, cervical, and sacral spine were found in 4 (15.4%), 11 (42.3%), 15 (57.7%), and 5 (19.2%) patients, respectively (Fig. 1b). Lesions of pelvis were detected in 9 (34.6%) patients, with 7 (26.9%) and 4 (15.4%) patients having lesions on sacroiliac joint (Fig. 1c) and ilium, respectively. Four (15.4%) patients showed abnormal 18F-FDG uptake located in other non-axial sites. The SUVmax of the skeletal lesions ranged from 1.2 to 17.1,
with a majority (92.3%) of patients exhibiting low to moderate 
$^{18}$F-FDG uptake, yet one patient exhibits intense uptake 
(SUVmax 13.1) and one very intense uptake (SUVmax 17.
1). The structural part of PET/CT demonstrated features of 
both acute inflammation, such as osteolysis and soft tissue 
edema, and chronic inflammation, osteosclerosis, and 
hyperostosis (Table 2 and Additional file 1: Table S1).

Sixteen (61.5%) patients had abnormal $^{18}$F-FDG 
uptake outside the osteoarticular system (Fig. 2). The 
tonsil (Fig. 1d), pharynx, nose, paranasal sinus, and 
lymph nodes were the most common affected sites, with 
a combined percentage of 34.6%. Five (19.2%) patients 
showed abnormal $^{18}$F-FDG uptake in the thyroid and 4 
(15.4%) in the gastrointestinal tract.

**Agreement between PET/CT, WBBS, and clinical 
symptoms**

The agreement between functional and structural parts 
of PET/CT was substantial in revealing lesions in the 
cervical spine ($\kappa = 0.75$), thoracic spine ($\kappa = 0.77$), sacral 
spine ($\kappa = 0.79$), and sacroiliac joint ($\kappa = 0.80$). Moderate 
agreement was reached for the lumbar spine ($\kappa = 0.53$) 
and ACW ($\kappa = 0.45$).

As to the clinical symptoms, $^{18}$F-FDG PET showed only 
fair agreement with concurrent symptoms for lesions in 
the ACW ($\kappa = 0.24$) and thoracic spine ($\kappa = 0.30$); 75.0 and 
34.8% of the asymptomatic patients in these regions 
showed increased $^{18}$F-FDG uptake, respectively. Even 
more slight agreement was found for lesions in the 
sacroiliac joint ($\kappa = 0.17$)—a majority (63.6%) of patients 
with lumbosacral symptoms did not show increased $^{18}$F-
FDG uptake in the sacroiliac joint. On the other hand, 
moderate agreement was shown for lesions in the cervical 
spine ($\kappa = 0.51$), lumbar spine ($\kappa = 0.55$), and sacral spine 
($\kappa = 0.49$).

In terms of the correlation between $^{18}$F-FDG PET and 
WBBS, moderate to substantial agreement was reached 
for spinal lesions: cervical spine ($\kappa = 0.70$), thoracic spine 
($\kappa = 0.77$), lumbar spine ($\kappa = 0.44$), and sacral spine ($\kappa = 0.
42$). Nonetheless, only fair agreement was shown for 
sacroiliac joint ($\kappa = 0.35$). The $\kappa$ coefficient was rather low 
($\kappa = -0.06$) for lesions in the ACW due to substantial 
imbalance in the table's marginal totals [24], yet the 
positive agreement was as high as 91.7% (Table 3).

**Discussion**

This was the largest study investigating the characteristics 
of SAPHO syndrome on $^{18}$F-FDG PET/CT. We found 
multiple skeletal lesions affecting the ACW or spine with 
low to moderate $^{18}$F-FDG uptake and coexistence of 
osteolysis and osteosclerosis as typical features of SAPHO 
syndrome. PET imaging had moderate to substantial
agreement with CT and WBBS in revealing the ACW and axial skeletal lesions in SAPHO syndrome. Nonetheless, the correlation between increased 18F-FDG uptake and clinical symptoms was weak.

As to the clinical picture, we found that SAPHO syndrome mainly affected middle-aged females, in accordance with previous studies [7, 25, 26]. The ACW was the main target skeletal site, followed by spine and sacroiliac joints, consistent with the disease's predilection for axial skeleton [3, 27]. Only one patient was free of dermatological symptoms, less than other cohorts [7, 25–27] but similar to our cohort reported previously [28]. PPP was the most common skin manifestation, followed by SV and PV. In line with current literature, SAPHO syndrome presented no association with HLA-B27, which was distinct from seronegative spondyloarthropathy [25, 28].

### Table 2
Demographic, clinical, and imaging characteristics of the 26 patients with SAPHO syndrome

| Characteristic                              | Value          | Percentage |
|--------------------------------------------|----------------|------------|
| Age at onset (years)                       | 44.6 ± 11.1    |            |
| Gender, female                             | 20 (74.1%)     |            |
| Age at performing PET/CT, years            | 47.9 ± 10.8    |            |
| Skin lesions                               | 25 (96.2)      |            |
| PPP                                        | 23 (88.5%)     |            |
| SA                                         | 4 (15.4%)      |            |
| PV                                         | 2 (7.7%)       |            |
| Osteoarticular symptoms                    | 26 (100%)      |            |
| Anterior chest pain                        | 26 (100%)      |            |
| Cervical region pain                       | 6 (23.1%)      |            |
| Thoracic region pain                       | 12 (46.2%)     |            |
| Lumbosacral region pain                    | 21 (80.8%)     |            |
| Hip pain                                   | 9 (34.6%)      |            |
| Others                                     | 6 (19.2%)      |            |
| Laboratory findings                        |                |            |
| ESR, mm/h                                  | 46.9 ± 8.2     |            |
| CRP, mg/L                                  | 22.4 ± 7.9     |            |
| HLA-B27, positive                          | 0 (0%)         |            |
| Bone scintigraphy                          | 25             |            |
| ACW                                        | 25 (100%)      |            |
| LS                                         | 16 (61.5%)     |            |
| TS                                         | 12 (46.2%)     |            |
| SI                                         | 8 (32.0%)      |            |
| CS                                         | 4 (16.0%)      |            |
| SS                                         | 3 (12.0%)      |            |
| Femur                                      | 2 (8.0%)       |            |
| Ilium                                      | 2 (8.0%)       |            |
| Knee                                       | 2 (8.0%)       |            |
| Other                                      | 5 (19.2%)      |            |
| PET/CT                                     | 26 (100%)      |            |
| Osteoarticular abnormalities               |                |            |
| Sites of increased tracer uptake           |                |            |
| ACW                                        | 23 (88.5%)     |            |
| LS                                         | 15 (57.7%)     |            |
| TS                                         | 11 (42.3%)     |            |
| SI                                         | 7 (26.9%)      |            |

ACW includes the costochondral, sternoclavicular, manubriosternal, and costosternal articulation, sternum, clavicle, and anterior ribs

ACW anterior chest wall, SI sacroiliac, CS cervical spine, TS thoracic spine, LS lumbar spine, SS sacral spine, BMD bone marrow density
The characteristics of SAPHO syndrome on $^{18}$F-FDG PET/CT had only been described in limited case reports (Table 1). Our results showed most patients had multiple skeletal abnormalities. The ACW was the most commonly affected site on both functional and structural part of PET/CT, followed by the lumbar spine, thoracic spine, and sacroiliac joints. Such findings conformed with the results of WBBS and our large cohort study of 164 patients [28], but slightly differed from some reports that thoracic vertebrae were the most frequently involved segment of the spine [29]. In agreement with previous studies, the bone lesions were usually with low to moderate $^{18}$F-FDG uptake, yet very intense uptake (SUV > 15) could also present in rare cases. The coexistence of osteolysis and osteosclerosis were the major structural changes revealed by CT [9], suggesting a bone remodeling process in SAPHO syndrome [30].

We found that $^{18}$F-FDG PET imaging had moderate to substantial agreement with $^{99m}$Tc-MDP WBBS in revealing spinal lesions, despite of asynchrony of the two examinations. This might suggest a coupled abnormal glucose and diphosphonate metabolism in these regions. Such findings were also backed up by the good agreement between PET imaging and CT for axial skeletal lesions. Infiltration of inflammatory cells consuming excessive glucose causes increased local blood flow and pathological bone metabolism which finally results in structural changes [31]. Overall, $^{18}$F-FDG PET/CT exhibited comparable ability with WBBS in detecting osteoarticular lesions in SAPHO syndrome, though it had much higher spatial resolution.

In contrast, we found poor agreement between PET imaging and clinical symptoms. This might be partly explained by the existence of abundant subclinical lesions in SAPHO syndrome, especially for the ACW and spine [3, 9, 22]. Moreover, the lack of specificity of symptoms in the lumbosacral region might also contribute to the low agreement. On the other hand, it should also be noted that there exist a small number of symptomatic lesions that were negative on PET imaging. We hypothesized that these symptoms might be caused by remnant structural changes of inactive lesions, such as those causing nerve compression [32, 33].

Various stages of bone lesions have been reported in SAPHO syndrome, including acute inflammation, chronic inflammation, and a healing process with osteosclerosis and bone marrow fibrosis [26]. It has been considered that PET/CT is capable of differentiating active bone lesions from inactive ones—the chronic healing lesions present with normal $^{18}$F-FDG uptake [3, 13, 22]. However, our findings cast doubt on such a viewpoint since biopsy of lesions with augmented $^{18}$F-FDG uptake sometimes showed fibrosis or sclerosis. Considering that aspiration biopsy might not represent the whole picture of the involved regions, it is hard to tell whether PET/CT can actually reveal inactive lesions and further investigation is needed.

Extra-osteoarticular abnormalities were revealed in more than 60% patients by PET/CT, which had seldom been reported previously. Although SAPHO syndrome is defined as a disorder of bone and skin, whole-body PET/CT allowed us to look into the disease in a systemic picture. Tonsillitis has been reported to be related to the onset and exacerbation of PPP [34, 35]. In a case report by Shiraishi et al., a patient with SAPHO syndrome and hypertrophic pachymeningitis showed complete remission of both diseases after bilateral tonsillectomy [36]. Our findings also provided new data for the hypothesis that SAPHO syndrome might be related to focal inflammation such as tonsillitis and sinusitis. We also discovered thyroid abnormalities on PET/CT in around 1/5 patients. The prevalence of antithyroid antibodies has been reported to be as high as 28% in an Italian cohort of SAPHO syndrome [25], but considerably lower (~ 3%) in other studies [37, 38]. Our findings again raised the concern for thyroid disorder in SAPHO syndrome.
Generally, PET scan is considered to be a safe procedure with no known long-term adverse effects. Some potential risks include bleeding and allergic reactions, which are extremely rare. However, the high cost is a major disadvantage and currently limiting its clinical utility.

There were several limitations to this study. First, the imaging assessments were performed in multiple centers, which may cause bias in imaging collection and interpretation. However, as \(^{18}\)F-FDG PET/CT is not a routine test for this rare disease—it is usually used for difficult differential diagnosis in clinical practice, it is rather hard to collect data in a single center. Further studies with rigorous imaging assessment are in need. Second, the \(^{18}\)F-FDG PET/CT and WBBS were not performed synchronously, which

### Table 3 Agreement between PET/CT, whole-body bone scintigraphy, and clinical symptoms

| Symptom       | PET/CT functional part | k  | 95% CI Negative agreement (%) | 95% CI Positive agreement (%) |
|---------------|------------------------|----|------------------------------|-------------------------------|
| Anterior chest wall | − 2 6 0.24 − 0.14–0.61 36.4 82.9 |
| WBBS          | − 0 1 − 0.06 − 0.16–0.03 0 91.7 |
| PET/CT structural part | − 3 22 0.45 0.09–0.81 54.5 87.8 |
| Cervical spine | − 21 2 0.51 0.02–0.99 93.3 57.1 |
| WBBS          | − 21 1 0.70 0.32–1.00 95.5 75.0 |
| PET/CT structural part | − 20 0 0.75 0.44–1.00 95.2 80.0 |
| Thoracic spine | − 15 8 0.30 0.01–0.59 78.9 42.9 |
| WBBS          | − 13 1 0.77 0.52–1.00 89.7 87.0 |
| PET/CT structural part | − 13 1 0.77 0.52–1.00 89.7 87.0 |
| Lumbar spine  | − 10 5 0.55 0.25–0.85 76.9 76.9 |
| WBBS          | − 7 3 0.44 0.09–0.79 66.7 77.4 |
| PET/CT structural part | − 8 3 0.53 0.20–0.86 72.7 80.0 |
| Sacral spine  | − 15 0 0.49 0.18–0.80 83.3 62.5 |
| WBBS          | − 20 3 0.42 0.05–0.88 90.9 50.0 |
| PET/CT structural part | − 19 0 0.79 0.51–1.00 95.0 83.3 |
| Sacroiliac joint | − 12 3 0.17 0.19–0.54 70.6 44.4 |
| WBBS          | − 15 3 0.17 0.05–0.74 81.1 53.3 |
| PET/CT structural part | − 18 1 0.80 0.55–1.00 94.7 85.7 |

WBBS whole-body bone scintigraphy
lead to inaccuracy when analyzing agreement. Further gathering of data is needed to support such analysis.

Conclusions

In summary, SAPHO syndrome exhibits characteristic features on 18F-FDG PET/CT. It showed comparable capacity in revealing skeletal lesions with bone scintigraphy. However, the correlation between increased 18F-FDG uptake and clinical symptoms was weak.

Additional file

Additional file 1: Table S1. Clinical characteristics, imaging features and pathological findings of 26 patients with SAPHO syndrome. (DOC 84 kb)

Acknowledgements

The authors thank K. Anandalingam for her contribution to the revision of the article.

Funding

C Li is currently receiving a grant 2016-4-40112 from Capital Medical Research and Development Fund and a grant 2016YFC0901501 from the National Key Research and Development Program of China. W Zhang is currently receiving a grant 2017-I2M-3-003 from the CAMS Initiative for Innovative Medicine. H JIng is currently receiving a grant 81501513 from the National Natural Science Foundation of China.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

XS, CL, and YC contributed equally to this study. CL conceived and designed the study. CL, XS, LL, and HJ contributed to the acquisition of the clinical and imaging data. XS and YC analyzed and interpreted the patient data and drafted the manuscript. WZ, XW, and NW revised the draft with some important intellectual suggestions. WZ critically revised the draft finally and gave approval of the final version. All authors read and approved the final manuscript.

Ethics approval and consent to participate

A written informed consent was obtained from each patient. The Ethics Committee of Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, approved this study (number of Ethics documents: ZS-944).

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Rheumatology and Clinical Immunology, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People’s Republic of China. 2Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People’s Republic of China. 3Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People’s Republic of China. 4Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People’s Republic of China. 5Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People’s Republic of China. 6Department of Orthopaedics, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People’s Republic of China. 7Department of Thoracic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People’s Republic of China. 8Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing 100730, People’s Republic of China.

Received: 6 February 2018 Accepted: 29 March 2018

Published online: 22 May 2018

References

1. Chomat A, Benhamou C, Kahn M, Beraneck L, Kaplan G, Prost A. Acne-pustulosis-hyperostosis-ostitis syndrome. Results of a national survey. 85 cases. Revue du rhumatisme et des maladies ostéo-articulaires. 1987; 54(3):187–96.
2. Chen L, YiHai C, Wen Z. Clinical heterogeneity of SAPHO syndrome: challenge of diagnosis. Mod Rheumatol. 2018. https://doi.org/10.1080/14397596.2017.1416733.
3. Schaub S, Sirkis HM, Kay J. Imaging for synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. Rheum Dis Clin N Am. 2016;42(4):695–710.
4. Kahn MF, Khan MA. The SAPHO syndrome. Baillieres Clin Rheumatol. 1994; 8(2):333–62.
5. Magrey M, Khan MA. New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. Curr Rheumatol Rep. 2009;11(5):329–33.
6. Van Doornum S, Barraclough D, McColl G, Wicks I. SAPHO: rare or just not recognized? Semin Arthritis Rheum. 2000;30(1):70–7.
7. Witt M, Meier J, Hammitzsch A, Proft F, Schulze-Koops H, Grunke M. Disease burden, disease manifestations and current treatment regimen of the SAPHO syndrome in Germany: results from a nationwide patient survey. Semin Arthritis Rheum. 2014;43(6):745–50.
8. Khanna L, El-khoury GY. SAPHO syndrome—a pictorial essay. Iowa Orthop J. 2012;32:189.
9. Xu W, Li C, Zhao X, et al. Whole-spine computed tomography findings in SAPHO syndrome. J Rheumatol. 2017;44(5):648–54.
10. Kohlfuerst S, Igerc I, Lind P. FDG PET helpful for diagnosing SAPHO syndrome. Clin Nucl Med. 2003;28(10):838–9.
11. Pichler R, Weiglein K, Schmelk B, Sfetsos K, MascheK W. Bone scintigraphy using Tc-99m DPD and F18-FDG in a patient with a SAPHO patient. Scand J Rheumatol. 2003;32(5):58–60.
12. Shibakuli K, Seto T, Uematsu K, et al. Pulmonary adenocarcinoma associated with SAPHO syndrome difficult to differentiate from multiple bone metastasis. Intern Med. 2006;45(8):543–6.
13. Inoue K, Yamaguchi T, Ozawa H, et al. Diagnosis of active inflammation in the SAPHO syndrome using 18F-FDG-PET/CT in suspected metastatic vertebral bone tumors. Ann Nucl Med. 2007;21(8):477–80.
14. Takeuchi K, Matusita M, Takagishi K. A case of SAPHO (synovitis-acne-pustulosis-hyperostosis-osteomyelitis) syndrome in which [18F]fluorodeoxyglucose positron emission tomography was useful for differentiating from multiple metastatic bone tumors. Mod Rheumatol. 2007;17(1):67–71.
15. Patel CN, Smith JT, Rankine JJ, Scarsbrook AF. F-18 FDG PET/CT can help differentiate SAPHO syndrome from suspected metastatic bone disease. Clin Nucl Med. 2009;34(4):254–7.
16. Abuhid IM, Silva LC, Martins GP, de Rezende NA. Diagnosing SAPHO syndrome in suspected metastatic bone tumors. Clin Nucl Med. 2010; 35(3):172–4.
17. Canbaz F, Gonullu G, Baris S, Selcuk MB, Bicakci N. SAPHO syndrome without dermatologic manifestations: multifocal uptake mismatch on 99mTc-MDP and 18FDG-FDG-PET/CT imaging. Helli J Nucl Med. 2010;1(1):73.
18. J-H N, Yamada K, Mitsuji N, Saito T. A case of SAPHO syndrome with destructive spondylodiscitis suspicious of tuberculous spondylitis. Mod Rheumatol. 2010;20(1):93–7.
19. Narimakol G, Ishii M, Takasa S, Betsuyaka T. The diagnostic usefulness of 18F-fluorodeoxyglucose-positron emission tomography/CT in SAPHO syndrome. BMJ Case Rep. 2013;2015;2015:0.1416733.
20. Ikeda K, Yamagata M, Tanaka S, Yokota M, Furuta S, Nakajima H. Synovitis and osteitis in the left sternoclavicular joint in a 60-year-old woman. J Med Ultrason. 2015;42(1):133–4.
21. Dong A, Bai Y, Cui Y, Zhang J, Zhuo C. FDG PET/CT in early and late stages of SAPHO syndrome: two case reports with MRI and bone scintigraphy correlation. Clin Nucl Med. 2016;41(4):e211–e5.
22. Depasquale R, Kumar N, Lalam RK, et al. SAPHO: what radiologists should know. Clin Radiol. 2012;67(3):195–206.
23. Cicchetti DV, Feinstein AR. High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol. 1990;43(6):551–8.
24. Feinstein AR, Cicchetti DV. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol. 1990;43(6):543–9.
25. Colina M, Govoni M, Orzincolo C, Trotta F. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Care Res. 2009;61(6):813–21.
26. Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum. 1999;29(3):159–71.
27. Okuno H, Watanuki M, Kuwahara Y, et al. Clinical features and radiological findings of 67 patients with SAPHO syndrome. Mod Rheumatol. 2017; https://doi.org/10.1080/14397595.2017.1372874.
28. Li C, Zuo Y, Wu N, et al. Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a single centre study of a cohort of 164 patients. Rheumatology. 2016;55(6):1023–30.
29. McGavran A, Kotsenas A, Diehn F, Wald J, Carr C, Morris J. SAPHO syndrome: imaging findings of vertebral involvement. Am J Neuroradiol. 2016;37(8):1567–72.
30. Anić B, Padjen I, Mayer M, Bosnić D, Cerovec M. Clinical features of the SAPHO syndrome and their role in choosing the therapeutic approach: report of four patients and review of the literature. Acta Dermatovenerol Croat. 2014;23(3):180–8.
31. Nguyen MT, Borchers A, Selmi C, Naguwa SM, Cheema G, Gershwin ME. The SAPHO syndrome. Semin Arthritis Rheum. 2012;42(3):254–65.
32. Fuji T, Matsuda A, Oda H, Seichi A, Nakamura K. A case of SAPHO syndrome with paraplegia due to a thoracic kyphosis. Ryumachi. 2002;42(4):687–93.
33. Takigawa T, Tanaka M, Nakahara S, Sugimoto Y, Ozaki T. SAPHO syndrome with rapidly progressing destructive spondylitis: two cases treated surgically. Eur Spine J. 2008;17(2):331–7.
34. Yamamoto T. Pustulotic arthro-ostitis associated with palmoplantar pustulosis. J Dermatol. 2013;40(11):857–63.
35. Shiraishi W, Hayashi S, Iwanaga Y, Murai H, Yamamoto A, Kira J. A case of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome presenting with hypertrophic pachymeningitis. J Neurol Sci. 2015;349(1-2):229–31.
36. Sun et al. Journal of Orthopaedic Surgery and Research (2018) 13:120